Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roger J Packer

Showing results (221-230 of 279) with videos related to

Pageof 28
Sort By:
Neuro-Oncology|December 7, 2013
Efficacy of bevacizumab plus irinotecan in children with recurrent low-grade gliomas--a Pediatric Brain Tumor Consortium studySridharan Gururangan, Jason Fangusaro, Tina Young Poussaint, et al.
Neuro-Oncology|February 15, 2020
Implications of new understandings of gliomas in children and adults with NF1: report of a consensus conferenceRoger J Packer, Antonio Iavarone, David T W Jones, et al.
Developmental Cell|August 24, 2021
Treatment during a developmental window prevents NF1-associated optic pathway gliomas by targeting Erk-dependent migrating glial progenitorsEmmanuelle S Jecrois, Wang Zheng, Miriam Bornhorst, et al.
Neuro-Oncology|April 28, 2017
Response assessment in medulloblastoma and leptomeningeal seeding tumors: recommendations from the Response Assessment in Pediatric Neuro-Oncology committeeKatherine E Warren, Gilbert Vezina, Tina Y Poussaint, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 20, 2007
Phase I and pharmacokinetic study of the oral farnesyltransferase inhibitor lonafarnib administered twice daily to pediatric patients with advanced central nervous system tumors using a modified continuous reassessment method: a Pediatric Brain Tumor Consortium StudyMark W Kieran, Roger J Packer, Arzu Onar, et al.
American Journal of Medical Genetics. Part A|April 25, 2017
The path forward: 2015 International Children's Tumor Foundation conference on neurofibromatosis type 1, type 2, and schwannomatosisJaishri O Blakeley, Annette Bakker, Anne Barker, et al.
JAMA Oncology|July 22, 2021
Efficacy of Carboplatin and Isotretinoin in Children With High-risk Medulloblastoma: A Randomized Clinical Trial From the Children's Oncology GroupSarah E S Leary, Roger J Packer, Yimei Li, et al.
Neuro-Oncology|March 25, 2017
A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) studyAnuradha Banerjee, Regina I Jakacki, Arzu Onar-Thomas, et al.
Neuro-Oncology Advances|October 22, 2025
Challenges in diagnostics and treatment of infant-type hemispheric gliomasLudmila Papusha, Margarita Zaytseva, Maria Senchenko, et al.
Annals of Neurology|April 18, 2014
Gender as a disease modifier in neurofibromatosis type 1 optic pathway gliomaMichael J Fisher, Michael Loguidice, David H Gutmann, et al.
Pageof 28

Showing results (221-230 of 279) with videos related to

Sort By:
Pageof 28
Neuro-Oncology|December 7, 2013
Efficacy of bevacizumab plus irinotecan in children with recurrent low-grade gliomas--a Pediatric Brain Tumor Consortium studySridharan Gururangan, Jason Fangusaro, Tina Young Poussaint, et al.
Neuro-Oncology|February 15, 2020
Implications of new understandings of gliomas in children and adults with NF1: report of a consensus conferenceRoger J Packer, Antonio Iavarone, David T W Jones, et al.
Developmental Cell|August 24, 2021
Treatment during a developmental window prevents NF1-associated optic pathway gliomas by targeting Erk-dependent migrating glial progenitorsEmmanuelle S Jecrois, Wang Zheng, Miriam Bornhorst, et al.
Neuro-Oncology|April 28, 2017
Response assessment in medulloblastoma and leptomeningeal seeding tumors: recommendations from the Response Assessment in Pediatric Neuro-Oncology committeeKatherine E Warren, Gilbert Vezina, Tina Y Poussaint, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 20, 2007
Phase I and pharmacokinetic study of the oral farnesyltransferase inhibitor lonafarnib administered twice daily to pediatric patients with advanced central nervous system tumors using a modified continuous reassessment method: a Pediatric Brain Tumor Consortium StudyMark W Kieran, Roger J Packer, Arzu Onar, et al.
American Journal of Medical Genetics. Part A|April 25, 2017
The path forward: 2015 International Children's Tumor Foundation conference on neurofibromatosis type 1, type 2, and schwannomatosisJaishri O Blakeley, Annette Bakker, Anne Barker, et al.
JAMA Oncology|July 22, 2021
Efficacy of Carboplatin and Isotretinoin in Children With High-risk Medulloblastoma: A Randomized Clinical Trial From the Children's Oncology GroupSarah E S Leary, Roger J Packer, Yimei Li, et al.
Neuro-Oncology|March 25, 2017
A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) studyAnuradha Banerjee, Regina I Jakacki, Arzu Onar-Thomas, et al.
Neuro-Oncology Advances|October 22, 2025
Challenges in diagnostics and treatment of infant-type hemispheric gliomasLudmila Papusha, Margarita Zaytseva, Maria Senchenko, et al.
Annals of Neurology|April 18, 2014
Gender as a disease modifier in neurofibromatosis type 1 optic pathway gliomaMichael J Fisher, Michael Loguidice, David H Gutmann, et al.
Pageof 28